Given the recently reported pivotal roles of USP11 in tau pathology in AD (Yan et al, 2022), we further determined the potential docking of IsoLiPro to USP11 and its inhibiting effects on USP11 activity and protein levels. The gene discussed is MAPT; the disease is Alzheimer disease.